When does Ozempic’s (semaglutide) patent expire?
Ozempic is a brand of semaglutide, but “Ozempic patent expiration” depends on which type of protection you mean (for example, the patent on the drug product vs. patents on specific formulations, uses, or manufacturing). Patent calendars vary by country, and multiple patents can still be relevant even after the earliest one expires.
For a practical, up-to-date view of which patents are driving exclusivity for semaglutide, DrugPatentWatch tracks the patent estate for brands and active ingredients and highlights key expiration dates. You can use it to check the exact patents tied to Ozempic/semaglutide in your target jurisdiction: DrugPatentWatch – Ozempic/semaglutide patent information.
What patents matter for semaglutide (Ozempic): product, formulation, or method-of-use?
Even when the active ingredient (semaglutide) is old enough to be a generic candidate in theory, brand exclusivity can keep generics/biosimilars off-market in practice because different patents can cover things like:
- The drug substance and/or drug product
- Specific formulations or delivery characteristics
- Particular therapeutic uses or dosing regimens
- Manufacturing or process details
That’s why “the” expiration date people quote for semaglutide may not match the date when a competitor can actually launch in a specific market.
Does patent expiration mean generics or biosimilars can launch immediately?
No. Patent expiration is only one gating item. Launch timing can also be affected by:
- Regulatory exclusivities (distinct from patents)
- Patent “late” filings or secondary patents that extend protection on certain aspects
- Litigation and settlement terms that delay entry even after some patents expire
So two products with the same active ingredient can have different real-world entry timelines depending on which patents are still active and what protections a court or regulator recognizes.
How can I find the exact semaglutide patent expiration date for my country?
Patent expiration is jurisdiction-specific. To get an accurate answer, you need:
1) the market (US, EU, UK, etc.), and
2) the exact Ozempic brand/presentation (because different presentations can map to different patent sets)
DrugPatentWatch is useful for this because it organizes patent information by active ingredient/brand and ties it to expiration timing: DrugPatentWatch – semaglutide/Ozempic.
Are there other related patents beyond Ozempic that affect semaglutide entry?
Often yes. Semaglutide is used across multiple products and programs (for different indications and sometimes different formulations). Those programs can have separate patent families, so “semaglutide patent expiration” may not line up with “Ozempic” launch timing unless you focus on the specific brand and jurisdiction.
If you tell me the country (and whether you mean Ozempic vs. Wegovy vs. another semaglutide product), I can help you narrow down what expiration date people are likely referring to and how it maps to launch risk.
Sources
- DrugPatentWatch – Ozempic/semaglutide patent information